DSIP
Also known as: Delta Sleep-Inducing Peptide
Delta Sleep-Inducing Peptide — a nine-amino-acid peptide originally found in rabbit brain during sleep research. Promotes deep, restorative sleep (stage 3 sleep) while also helping with stress, pain perception, and cell damage from stress. One of the few peptides that specifically targets sleep quality rather than just causing drowsiness.
Dosage
100-200 mcg subcutaneous or intranasal 30 min before bed
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Get Research-Grade DSIP
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Delta Sleep Promotion
Enhances deep slow-wave sleep — the most restorative sleep phase.
Stress Reduction
Suppresses HPA axis activity and reduces cortisol secretion.
Opioid Modulation
May normalize endorphin/enkephalin balance — studied in withdrawal protocols.
Mechanism of Action
Delta Sleep-Inducing Peptide is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during electrically induced sleep in 1977. Despite decades of research, its precise molecular receptor has not been definitively identified, making DSIP unusual among well-studied peptides. However, its physiological effects have been extensively characterized.
DSIP's sleep-promoting mechanism involves modulation of the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission in sleep-regulating brain regions. It enhances GABAergic tone in the ventrolateral preoptic area (VLPO) — the brain's primary sleep-promoting nucleus — while reducing glutamatergic excitatory drive in wake-promoting areas like the lateral hypothalamus and locus coeruleus. The net effect is promotion of slow-wave (delta) sleep, characterized by high-amplitude, low-frequency (0.5-4 Hz) EEG oscillations. This is the deepest, most restorative sleep stage, during which growth hormone secretion peaks, memory consolidation occurs, and cellular repair processes are most active.
Beyond sleep, DSIP has significant neuroendocrine effects. It reduces cortisol secretion by suppressing corticotropin-releasing hormone (CRH) and ACTH release, lowering the activity of the hypothalamic-pituitary-adrenal (HPA) stress axis. This stress-reducing effect may itself contribute to sleep quality, as HPA axis hyperactivity is a common cause of insomnia and fragmented sleep. DSIP also modulates endogenous opioid signaling — it has been studied in opiate withdrawal protocols for its ability to normalize disturbed endorphin/enkephalin balance. Some research suggests it may regulate somatostatin release and interact with the orexin/hypocretin system, though these mechanisms are less well established. The paradox of DSIP is that despite its very short plasma half-life (15-25 minutes), sleep-promoting effects persist for hours, suggesting it triggers sustained changes in neural network activity or gene expression rather than requiring continuous receptor occupancy.
Regulatory Status
Not FDA approved. Research primarily from European studies (1970s–1990s). Available through research peptide suppliers.
Risks & Safety
Common
morning grogginess, vivid dreams, mild next-day drowsiness.
Serious
very limited human research data, long-term safety not established.
Rare
allergic reactions.
Compare DSIP With
Research Papers
5Published: December 31, 2025
AI Summary
A broad review explains how various therapeutic peptides—including delta sleep-inducing peptide—support tissue repair, inflammation control, and nerve recovery in musculoskeletal care. While animal studies look promising, human clinical trials are still lacking.
Published: October 7, 2024
AI Summary
Researchers tested a DSIP fusion peptide in a mouse insomnia model to evaluate its sleep-promoting and neurotransmitter-balancing effects. The fusion peptide was produced using Pichia pastoris and designed to cross the blood-brain barrier.
Published: October 25, 2023
AI Summary
A new peptide synthesis method was developed that reduces chemical waste and was demonstrated by synthesizing DSIP. The N-to-C approach offers cleaner, more atom-efficient peptide production without elaborate protecting groups.
Published: August 25, 2021
AI Summary
Intranasal DSIP did not significantly reduce brain infarction volume but did significantly improve motor recovery in rats after stroke. Eight days of treatment led to faster recovery of motor function in behavioral tests.
Published: April 8, 2021
AI Summary
A DSIP-like peptide called KND, given during reperfusion, reduced both heart and brain infarction in animal models. Giving these peptides during occlusion caused 100% mortality, so they should only be used during reperfusion.
Frequently Asked Questions
What is DSIP?
Delta Sleep-Inducing Peptide — a nine-amino-acid peptide originally found in rabbit brain during sleep research. Promotes deep, restorative sleep (stage 3 sleep) while also helping with stress, pain perception, and cell damage from stress. One of the few peptides that specifically targets sleep quality rather than just causing drowsiness.
What is DSIP used for?
Delta Sleep-Inducing Peptide — a nine-amino-acid peptide originally found in rabbit brain during sleep research. Promotes deep, restorative sleep (stage 3 sleep) while also helping with stress, pain perception, and cell damage from stress. One of the few peptides that specifically targets sleep quality rather than just causing drowsiness.
What is the dosage for DSIP?
Standard: 100-200 mcg subcutaneous or intranasal 30 minutes before bed. Often cycled 2-4 weeks on, 1-2 weeks off.
What are the side effects of DSIP?
Common: morning grogginess, vivid dreams, mild next-day drowsiness. Serious: very limited human research data, long-term safety not established. Rare: allergic reactions.
How does DSIP work?
Delta Sleep-Inducing Peptide is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during electrically induced sleep in 1977. Despite decades of research, its precise molecular receptor has not been definitively identified, making DSIP unusual among well-studied peptides. However, its physiological effects have been extensively characterized. DSIP's sleep-promoting mechanism involves modulation of the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission in sleep-regulating brain regions. It enhances GABAergic tone in the ventrolateral preoptic area (VLPO) — the brain's primary sleep-promoting nucleus — while reducing glutamatergic excitatory drive in wake-promoting areas like the lateral hypothalamus and locus coeruleus. The net effect is promotion of slow-wave (delta) sleep, characterized by high-amplitude, low-frequency (0.5-4 Hz) EEG oscillations. This is the deepest, most restorative sleep stage, during which growth hormone secretion peaks, memory consolidation occurs, and cellular repair processes are most active. Beyond sleep, DSIP has significant neuroendocrine effects. It reduces cortisol secretion by suppressing corticotropin-releasing hormone (CRH) and ACTH release, lowering the activity of the hypothalamic-pituitary-adrenal (HPA) stress axis. This stress-reducing effect may itself contribute to sleep quality, as HPA axis hyperactivity is a common cause of insomnia and fragmented sleep. DSIP also modulates endogenous opioid signaling — it has been studied in opiate withdrawal protocols for its ability to normalize disturbed endorphin/enkephalin balance. Some research suggests it may regulate somatostatin release and interact with the orexin/hypocretin system, though these mechanisms are less well established. The paradox of DSIP is that despite its very short plasma half-life (15-25 minutes), sleep-promoting effects persist for hours, suggesting it triggers sustained changes in neural network activity or gene expression rather than requiring continuous receptor occupancy.
How is DSIP administered?
DSIP is administered via subcutaneous injection or intranasal spray.
What is the half-life of DSIP?
The half-life of DSIP is 15-25 minutes (sleep-promoting effects persist throughout the night).
Is DSIP legal?
Not FDA approved. Research primarily from European studies (1970s–1990s). Available through research peptide suppliers.
Related Peptides
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
CJC-1295 (no DAC)
One of the most popular growth hormone peptides, often called Mod GRF 1-29. Instead of injecting growth hormone directly, this tells your pituitary gland to release more of its own GH naturally. This is considered healthier than injecting GH directly because your body keeps its normal feedback systems intact. Usually combined with Ipamorelin for much stronger effects — the two work together better than either alone.
CJC-1295 + Ipamorelin
The most commonly prescribed peptide combination in anti-aging and regenerative medicine. Pairs the GHRH analogue CJC-1295 (Mod GRF 1-29) with the selective ghrelin-mimetic Ipamorelin for synergistic, pulsatile growth hormone release. Exploits two complementary signaling pathways — cAMP (GHRH) and calcium/PLC (ghrelin receptor) — to amplify GH pulses while maintaining minimal side effects.
CJC-1295 with DAC
The long-acting version of CJC-1295. After injection it attaches to a protein in your blood (albumin), which keeps it active for nearly a week instead of just 30 minutes. This means you only need to inject once a week. The trade-off is that it keeps growth hormone elevated constantly rather than in natural pulses, which some practitioners consider less ideal for your body. More convenient but potentially less natural than the no-DAC version.